KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to 0.79.

  • Arbutus Biopharma's Equity Ratio rose 407.66% to 0.79 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.79, marking a year-over-year increase of 407.66%. This contributed to the annual value of 0.74 for FY2024, which is 69.06% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Equity Ratio stood at 0.79, which was up 407.66% from 0.8 recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Equity Ratio registered a high of 0.83 during Q4 2021, and its lowest value of 0.68 during Q1 2025.
  • Over the past 5 years, Arbutus Biopharma's median Equity Ratio value was 0.75 (recorded in 2023), while the average stood at 0.75.
  • Its Equity Ratio has fluctuated over the past 5 years, first surged by 1139.63% in 2021, then plummeted by 1548.53% in 2022.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Equity Ratio stood at 0.83 in 2021, then fell by 15.49% to 0.7 in 2022, then rose by 4.84% to 0.73 in 2023, then grew by 0.69% to 0.74 in 2024, then increased by 7.15% to 0.79 in 2025.
  • Its Equity Ratio stands at 0.79 for Q3 2025, versus 0.8 for Q2 2025 and 0.68 for Q1 2025.